Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Lehman who wrote (1029)	7/29/1998 7:21:00 AM
From: arthur a	Respond to of 1501

Harold: Your "thinking out loud" makes sense to me. (One point of exception: the following statement, which is provided for each of the main players, seems to indicate that the 16.5% ownership figure for each is after, not before, the exercise of the warrants.) "Assuming the exercise of the warrants held by the Purchaser and the issuance of an additional 2,020,298 common shares, the Purchaser beneficially owns and has control and direction over 16.5% of the outstanding common shares of Inflazyme."

To: Harold Lehman who wrote (1029)	7/29/1998 12:25:00 PM
From: David Graham	Respond to of 1501

Harold - FYI, info on Canadian banks. Royal Bank Capital Corp and Royal Trust are both subsidiaries of Royal Bank of Canada, which is the largest bank in Canada. Royal Bank Capital is a venture capital sub of the bank and has an interest in biotech/pharma companies. I don't know why Royal Trust is involved, they could be taking a position on behalf of a client, mutual funds or on their own account, although that would be strange in that it is separate from Royal Bank Capital Corp's stake. My guess is that neither is a particular "friend" of GS or Rothchilds. More likely, IZP worked hard to get some Canadian institution on board. There are huge (for the Canadian market) public and private pools of venture capital in Canada, and it has always struck me as odd that IZP couldn't get a piece of the pie. This is especially curious given that there is a biotech venture cap fund (Canadian Medical Discoveries C$250 million) and a larger, general venture cap fund (Working Ventures C$750 million) that invests part of its loot in biotech. The fact that IZP impressed a local group to invest tells me that Royal feels things are looking up. They must have been approached previously, unless Salari totally messed up, and now feel the time is right to invest. David